Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis

Q3 Medicine Digital Chinese Medicine Pub Date : 2021-10-01 DOI:10.1016/j.dcmed.2021.09.002
XIA Yu , LI Xin , MAN Rongyong , WANG Aibing , CAO Jianzhong
{"title":"Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis","authors":"XIA Yu ,&nbsp;LI Xin ,&nbsp;MAN Rongyong ,&nbsp;WANG Aibing ,&nbsp;CAO Jianzhong","doi":"10.1016/j.dcmed.2021.09.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>There are many clinical reports on traditional Chinese medicine (TCM) combined with nucleoside (acid) analogues (NAs) for the treatment of chronic hepatitis B (CHB), but its efficacy and safety are not completely clear. This meta-analysis aims to evaluate the clinical efficacy and safety thus providing evidence for clinical applications.</p></div><div><h3>Methods</h3><p>We searched Chinese databases the China National Knowledge Infrastructure (CNKI), Wanfang Data, and China Science and Technology Journal Database (VIP), as well as English databases PubMed and Cochrane Library, from time of establishment to April 14, 2021. Literature quality was evaluated according to the bias risk assessment criteria of Cochrane Collaboration network. RevMan 5.3 and Stata 12.0 software were used to perform this research.</p></div><div><h3>Results</h3><p>A total of 23 articles, 3 282 patients, and 25 TCM prescriptions were included in this study. NAs plus TCM remarkably improved the clinical total effective rate [Odds ratio (OR) = 3.92, <em>P</em> &lt; 0.000 01], TCM syndrome score (Mean difference = − 3.73, <em>P</em> &lt; 0.000 01), hepatitis B virus (HBV) DNA negative conversion rate (OR = 1.49, <em>P</em> = 0.000 1), hepatitis Be antigen (HBeAg) negative conversion rate (OR = 2.03, <em>P</em> &lt; 0.000 01), alanine aminotransferase levels [Std mean difference (SMD) = − 0.95, <em>P</em> &lt; 0.000 01], and aspartate aminotransferase levels (SMD = − 0.70, <em>P</em> = 0.000 4). Adverse reaction rates did not increase in the combined treatment group (OR = 0.97, <em>P</em> = 0.84). A comprehensive analysis of the 25 TCM prescriptions suggested that the combination of spleen-strengthening prescriptions with NAs showed better effects than other prescriptions.</p></div><div><h3>Conclusion</h3><p>TCM in combination with NAs, demonstrated better clinical efficacy against CHB than NAs alone. In addition, the combination of spleen-strengthening prescriptions and NAs was identified as the best therapeutic strategy. However, more randomized controlled trials of high quality are needed to provide more reliable clinical basis for the application of TCM.</p></div>","PeriodicalId":33578,"journal":{"name":"Digital Chinese Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589377721000306/pdfft?md5=0dc3e341b7edc153cf3e8facef3ebff5&pid=1-s2.0-S2589377721000306-main.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digital Chinese Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589377721000306","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Objective

There are many clinical reports on traditional Chinese medicine (TCM) combined with nucleoside (acid) analogues (NAs) for the treatment of chronic hepatitis B (CHB), but its efficacy and safety are not completely clear. This meta-analysis aims to evaluate the clinical efficacy and safety thus providing evidence for clinical applications.

Methods

We searched Chinese databases the China National Knowledge Infrastructure (CNKI), Wanfang Data, and China Science and Technology Journal Database (VIP), as well as English databases PubMed and Cochrane Library, from time of establishment to April 14, 2021. Literature quality was evaluated according to the bias risk assessment criteria of Cochrane Collaboration network. RevMan 5.3 and Stata 12.0 software were used to perform this research.

Results

A total of 23 articles, 3 282 patients, and 25 TCM prescriptions were included in this study. NAs plus TCM remarkably improved the clinical total effective rate [Odds ratio (OR) = 3.92, P < 0.000 01], TCM syndrome score (Mean difference = − 3.73, P < 0.000 01), hepatitis B virus (HBV) DNA negative conversion rate (OR = 1.49, P = 0.000 1), hepatitis Be antigen (HBeAg) negative conversion rate (OR = 2.03, P < 0.000 01), alanine aminotransferase levels [Std mean difference (SMD) = − 0.95, P < 0.000 01], and aspartate aminotransferase levels (SMD = − 0.70, P = 0.000 4). Adverse reaction rates did not increase in the combined treatment group (OR = 0.97, P = 0.84). A comprehensive analysis of the 25 TCM prescriptions suggested that the combination of spleen-strengthening prescriptions with NAs showed better effects than other prescriptions.

Conclusion

TCM in combination with NAs, demonstrated better clinical efficacy against CHB than NAs alone. In addition, the combination of spleen-strengthening prescriptions and NAs was identified as the best therapeutic strategy. However, more randomized controlled trials of high quality are needed to provide more reliable clinical basis for the application of TCM.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药方剂联合核苷(酸)类似物治疗慢性乙型肝炎的临床疗效及安全性荟萃分析
目的中药联合核苷(酸)类似物治疗慢性乙型肝炎(CHB)的临床报道较多,但其疗效和安全性尚不完全清楚。本荟萃分析旨在评价其临床疗效和安全性,为临床应用提供依据。方法检索中国知网(CNKI)、万方数据、中国科技期刊库(VIP)等中文数据库,以及PubMed、Cochrane Library等英文数据库,检索时间为研究成立至2021年4月14日。根据Cochrane协作网的偏倚风险评估标准评价文献质量。本研究采用RevMan 5.3和Stata 12.0软件进行。结果共纳入文献23篇,患者3 282例,中药处方25个。NAs联合中药显著提高临床总有效率[优势比(OR) = 3.92, P <0.000 01],中医证候评分(平均差异= - 3.73,P <乙型肝炎病毒(HBV) DNA阴性转换率(OR = 1.49, P = 0.000 1)、乙型肝炎抗原(HBeAg)阴性转换率(OR = 2.03, P <0.000 01),丙氨酸转氨酶水平[Std平均差(SMD) = - 0.95, P <[0.000 01]、天冬氨酸转氨酶水平(SMD = - 0.70, P = 0.000 4)。联合治疗组不良反应发生率未增加(OR = 0.97, P = 0.84)。综合分析25个中药方剂,健脾方与NAs合用疗效优于其他方剂。结论中药联合NAs治疗慢性乙型肝炎的临床疗效优于单用NAs。此外,健脾方联合NAs是最佳治疗策略。然而,需要更多高质量的随机对照试验,为中医药的应用提供更可靠的临床依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Digital Chinese Medicine
Digital Chinese Medicine Medicine-Complementary and Alternative Medicine
CiteScore
1.80
自引率
0.00%
发文量
126
审稿时长
63 days
期刊最新文献
Distribution of traditional Chinese medicine pattern types and prognostic risk factors in patients undergoing percutaneous coronary intervention (PCI): a systematic review and meta-analysis Research status and prospect of tongue image diagnosis analysis based on machine learning Thoughts on the system construction of digital Chinese medicine Differences in pulse manifestations at Cunkou based on simplified modeling of tactile sensing A novel deep learning based cloud service system for automated acupuncture needle counting: a strategy to improve acupuncture safety
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1